Amphastar Pharmaceuticals, Inc.

Name: Amphastar Pharmaceuticals, Inc. standardized financial statements, quarterly
Creator: Listed

AMPHNasdaqCIK 1297184HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$183.9m, Q2 FY2026

Operating income$39.7m, Q2 FY2026

Net income$30.3m, Q2 FY2026

Amphastar Pharmaceuticals, Inc., income statement, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Revenue	$m	181	178	172	182	191	187	171	174	192	183	171	184
Cost of revenue	$m	72.2	82.0	81.7	87.2	89.3	99.9	85.3	87.9	93.2	97.4	101	90.4
Gross profit	$m	108	96.1	90.1	95.2	102	86.6	85.3	86.5	98.6	85.7	70.3	93.5
Research and development	$m	16.7	20.4	17.0	17.7	21.1	18.1	20.1	20.1	22.4	23.3	26.7	22.2
Operating income	$m	72.7	54.0	48.0	55.2	57.0	45.1	37.3	42.2	25.3	35.6	13.6	39.7
Interest expense	$m	13.7	9.5	8.6	8.6	6.7	6.4	6.3	6.3	6.3	6.6	6.6	6.7
Income tax	$m	14.0	4.7	4.1	12.3	7.3	6.0	5.6	8.3	4.2	7.5	3.6	8.2
Net income	$m	49.2	36.2	43.2	37.9	40.4	38.0	25.3	31.0	17.4	24.4	6.4	30.3
Diluted EPS	$ per share	0.91	not reported	0.81	0.73	0.78	not reported	0.51	0.64	0.37	not reported	0.14	0.67
Basic EPS	$ per share	1.01	not reported	0.90	0.77	0.83	not reported	0.53	0.66	0.38	not reported	0.14	0.69

Balance sheet

Cash and equivalents$223.6m, Q2 FY2026

Long-term debt$619.7m, FY2025

Shareholders' equity$768.2m, Q2 FY2026

Amphastar Pharmaceuticals, Inc., balance sheet, quarterly
Line item	Unit	Q3 FY20232023-09-30	FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$m	267	144	201	190	192	152	183	188	216	170	171	224
Current assets	$m	543	490	555	483	546	534	588	581	639	636	634	631
Total assets	$m	1,545	1,513	1,574	1,492	1,545	1,577	1,626	1,615	1,666	1,629	1,648	1,744
Current liabilities	$m	258	225	255	137	159	174	199	176	205	158	164	263
Total liabilities	$m	949	873	902	778	818	845	875	858	889	840	875	976
Long-term debt	$m	653	603	not reported	not reported	not reported	614	not reported	not reported	not reported	620	not reported	not reported
Shareholders' equity	$m	595	639	672	713	728	732	751	757	777	789	773	768

Cash flow

Operating cash flow$51.3m, Q2 FY2026

Capital expenditure$8.6m, Q2 FY2026

Share repurchases$45.2m, Q2 FY2026

Amphastar Pharmaceuticals, Inc., cash flow, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$m	64.3	23.9	55.3	69.1	60.0	29.0	35.1	35.6	52.6	32.9	47.8	51.3
Capital expenditure	$m	10.2	9.4	8.8	6.0	13.8	12.4	10.7	10.6	5.3	8.3	9.5	8.6
Share repurchases	$m	50.0	0.0	not reported	not reported	35.0	42.0	11.0	39.2	4.9	20.5	29.5	45.2

Diluted shares (weighted)44.23m, Q2 FY2026

Amphastar Pharmaceuticals, Inc., shares, quarterly
Line item	Unit	Q3 FY20222022-09-30	Q1 FY20232023-03-31	Q2 FY20232023-06-30	Q3 FY20232023-09-30	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Diluted shares (weighted)	m shares	52.8	52.0	53.1	53.9	53.0	52.0	51.9	49.9	48.1	47.7	46.5	44.2

Shares outstanding: 42.54m at Jul 31, 2026, from the cover of the 10-Q filed Aug 6, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:36 ET. Listed shows no prices and gives no investment advice.